Cargando…

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

The analysis aimed at identifying subject‐specific characteristics (covariates) influencing exposure to daridorexant and quantification of covariate effects to determine clinical relevance. Data from 13 phase I, two phase II, and two phase III studies were pooled to develop a population pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krause, Andreas, Lott, Dominik, Brussee, Janneke M., Muehlan, Clemens, Dingemanse, Jasper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835129/ https://www.ncbi.nlm.nih.gov/pubmed/36309969 http://dx.doi.org/10.1002/psp4.12877

Ejemplares similares

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022)

Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
por: Muehlan, Clemens, et al.
Publicado: (2022)

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
por: Dingemanse, Jasper, et al.
Publicado: (2014)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Daridorexant: First Approval
por: Markham, Anthony
Publicado: (2022)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking
por: Khoo, Shaun Yon-Seng, et al.
Publicado: (2017)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

Correction to: Daridorexant: First Approval
por: Markham, Anthony
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension
por: Krause, A, et al.
Publicado: (2017)

Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2017)

Differential sleep-promoting effects of dual orexin receptor antagonists and GABA(A) receptor modulators
por: Gotter, Anthony L, et al.
Publicado: (2014)

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant
por: Dietrich, Hendrik, et al.
Publicado: (2010)

Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice
por: Duncan, Marilyn J., et al.
Publicado: (2019)

Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
por: Zhou, Mengzhen, et al.
Publicado: (2023)

Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
por: Rocha, Rebeka Bustamante, et al.
Publicado: (2023)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
por: Berger, Benjamin, et al.
Publicado: (2023)

Correction to: Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2019)

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
por: Gotter, Anthony L, et al.
Publicado: (2013)

Daridorexant in Insomnia Disorder: A Profile of Its Use
por: Nie, Tina, et al.
Publicado: (2023)

Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise
por: Martin, Tristan, et al.
Publicado: (2019)

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
por: Xue, Tao, et al.
Publicado: (2023)

Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review
por: Besterman, Aaron D., et al.
Publicado: (2021)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABA(A) and Glutamate Receptors
por: Razavi, Bibi Marjan, et al.
Publicado: (2020)

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
por: Hsin, Chih-hsuan, et al.
Publicado: (2023)

The Dual Orexin/Hypocretin Receptor Antagonist, Almorexant, in the Ventral Tegmental Area Attenuates Ethanol Self-Administration
por: Srinivasan, Subhashini, et al.
Publicado: (2012)

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
por: Kunz, Dieter, et al.
Publicado: (2022)

Correction to: Daridorexant in Insomnia Disorder: A Profile of Its Use
por: Nie, Tina, et al.
Publicado: (2023)

Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation
por: Beuckmann, Carsten Theodor, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uddurnqc0bar91ovb7596ohljs